【small straws in a soft wind daily】Aurobindo Pharma to recall 80 lots of blood pressure medicine valsartan in the US
时间:2024-09-29 08:14:05 出处:Leisure阅读(143)
Jan 2 (Reuters) - A U.S. unit of Indian generic drugmaker Aurobindo Pharma Ltd will recall 80 lots of medicines containing blood pressure drug valsartan that were found to have a probable cancer-causing impurity,small straws in a soft wind daily according to the U.S. Food and Drug Administration.
The impurity N-Nitrosodiethylamine (NDEA) was detected in quantities above the acceptable limit in certain tablets containing valsartan, the FDA said.
The announcement comes a month after Mylan NV said it will recall all lots of its blood pressure medicines containing valsartan, an angiotensin II receptor blocker, after global health authorities clamped down on the drug.
The health regulator said it will continue to investigate and test all angiotensin II receptor blockers for the presence of NDEA and another probable carcinogen N-nitrosodimethylamine.
In October last year, the FDA halted imports of drug ingredients or medicines containing ingredients produced at a factory of a Chinese bulk manufacturer of valsartan, Zhejiang Huahai Pharmaceuticals.
(Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Shinjini Ganguli)
View comments
上一篇: Is Sirius International Insurance (SG) A Good Stock To Buy Now?
下一篇: SNX or GWRE: Which Is the Better Value Stock Right Now?
猜你喜欢
- Green Stream Highlights Recent Video Presenting Company's Unique Solar Energy Solution
- Taking A Look At Cteh Inc.’s (HKG:1620) ROE
- N.Korea wanted most sanctions lifted in exchange for partial Yongbyon closure -U.S. official
- ECB will guarantee minimum liquidity for Greece until Sunday - Hollande
- Trintech Extends Reporting Capabilities in Its Adra Suite with the Launch of Adra Analytics
- Johnny Depp Rocks Out with Steven Tyler & Aerosmith in Boston
- Can S.M.R.E. S.p.A. (BIT:SMR) Improve Its Returns?
- Is Hawesko Holding AG’s (ETR:HAW) 11% ROCE Any Good?
- ESTA Announces Participation in the Goldman Sachs Global Healthcare Conference